| John Brent Forward, MD | |
|
195 Route #46, Ste #102, Mine Hill, NJ 07803-3164 | |
| (973) 366-6060 | |
| (973) 366-1423 |
| Full Name | John Brent Forward |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 43 Years |
| Location | 195 Route #46, Mine Hill, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477507192 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 45079 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atlantic Home Care & Hospice | Morristown, NJ | Home health agency |
| Saint Clare's Hospital/ Denville Campus | Denville, NJ | Hospital |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Internal Medicine Of Morris County Llc | 2466428388 | 51 |
| Prime Healthcare Services - Saint Clare's, Llc | 6406165372 | 8 |
News Archive
Neurofibrillary plaques and tau protein are among the most widely known pathological entities characterizing Alzheimer's disease (AD), but new research at the University of California, Riverside, has come up with another plausible explanation for this debilitating disorder.
Today's headlines and news coverage offer details about the House health law repeal debate, which started yesterday.
One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.
The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery (Prof. Tatsuya Yamasoba) and the group of Prof. Horacio Cabral of the Department of Bioengineering (Prof. Ryo Miyake) in the University of Tokyo that the efficacy of polymeric nano-micelles with different drug activation profile depends on the expression level of c-Myc, one of the major proto-oncogene, has been developed.
› Verified 9 days ago
| Entity Name | Internal Medicine Of Morris County Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568570489 PECOS PAC ID: 2466428388 Enrollment ID: O20040902000527 |
News Archive
Neurofibrillary plaques and tau protein are among the most widely known pathological entities characterizing Alzheimer's disease (AD), but new research at the University of California, Riverside, has come up with another plausible explanation for this debilitating disorder.
Today's headlines and news coverage offer details about the House health law repeal debate, which started yesterday.
One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.
The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery (Prof. Tatsuya Yamasoba) and the group of Prof. Horacio Cabral of the Department of Bioengineering (Prof. Ryo Miyake) in the University of Tokyo that the efficacy of polymeric nano-micelles with different drug activation profile depends on the expression level of c-Myc, one of the major proto-oncogene, has been developed.
› Verified 9 days ago
| Entity Name | Prime Healthcare Services - Saint Clare's, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497134274 PECOS PAC ID: 6406165372 Enrollment ID: O20151103001886 |
News Archive
Neurofibrillary plaques and tau protein are among the most widely known pathological entities characterizing Alzheimer's disease (AD), but new research at the University of California, Riverside, has come up with another plausible explanation for this debilitating disorder.
Today's headlines and news coverage offer details about the House health law repeal debate, which started yesterday.
One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.
The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery (Prof. Tatsuya Yamasoba) and the group of Prof. Horacio Cabral of the Department of Bioengineering (Prof. Ryo Miyake) in the University of Tokyo that the efficacy of polymeric nano-micelles with different drug activation profile depends on the expression level of c-Myc, one of the major proto-oncogene, has been developed.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Brent Forward, MD 195 Route #46, Ste #102, Mine Hill, NJ 07803-3164 Ph: (973) 366-6060 | John Brent Forward, MD 195 Route #46, Ste #102, Mine Hill, NJ 07803-3164 Ph: (973) 366-6060 |
News Archive
Neurofibrillary plaques and tau protein are among the most widely known pathological entities characterizing Alzheimer's disease (AD), but new research at the University of California, Riverside, has come up with another plausible explanation for this debilitating disorder.
Today's headlines and news coverage offer details about the House health law repeal debate, which started yesterday.
One of Mother Nature's latest gifts to medical science is stirring excitement with the discovery that the substance - obtained from a coral-reef inhabiting cyanobacterium - appears to be an ideal blueprint for developing new drugs for serious fractures, osteoporosis, and other bone diseases.
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's resubmission of the New Drug Application (NDA) for perampanel (E2007), an investigational drug, for the treatment of partial-onset seizures associated with epilepsy.
The Innovation Center of NanoMedicine (Director General: Prof. Kazunori Kataoka, Location: Kawasaki in Japan, Abbreviation: iCONM) reported in ACS Nano (Impact Factor: 14.588 in 2019) together with the group of Prof. Yu Matsumoto of Otorhinolaryngology and Head and Neck Surgery (Prof. Tatsuya Yamasoba) and the group of Prof. Horacio Cabral of the Department of Bioengineering (Prof. Ryo Miyake) in the University of Tokyo that the efficacy of polymeric nano-micelles with different drug activation profile depends on the expression level of c-Myc, one of the major proto-oncogene, has been developed.
› Verified 9 days ago
Dr. Tarun K Sharma, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Us Highway 46 Ste 100, Mine Hill, NJ 07803 Phone: 973-366-7330 Fax: 973-306-3043 | |
Dr. Aristides M Estrada, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Route #46, Ste #102, Mine Hill, NJ 07803 Phone: 973-366-6060 Fax: 973-366-1423 | |
Dr. Andreas D Rotsides, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Us Highway 46, Suite 200, Mine Hill, NJ 07803 Phone: 973-328-1040 Fax: 973-328-1544 | |
Nicholas S. Albicocco, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 195 Us Highway 46, Suite 203, Mine Hill, NJ 07803 Phone: 973-366-7330 Fax: 973-989-0508 | |
Dr. Subramoni Sundaram, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Us Highway 46, Suite 101, Mine Hill, NJ 07803 Phone: 973-361-2550 Fax: 973-361-0066 |